WW International, Inc. - Common Stock (WW)

With access to Registered Dietitians, 150+ New ZeroPoint® Foods and smarter tracking features, the new program delivers a cutting-edge, flexible approach to holistic weight management

Special guests include Rebel Wilson, Katie Sturino, Amber Riley, Marisa Meltzer, Jamie Kern Lima, Tressie McMillan Cottom, and leading medical and science experts Dr. Rachel Goldman and Dr. Ania Jastreboff

LifeMD stock is surging as the company is riding the GLP-1 trend to double-digit revenue growth and projections for 67% earnings growth in 2024

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of WW International Inc. (“Weight Watchers” or “the Company”) (NASDAQWW). Investors who purchased Weight Watchers securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/WW.

WW International Inc. (NASDAQWW) (WeightWatchers) has had a disastrous 2024, with its shares collapsing 66.7% year-to-date (YTD).

Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of WW International Inc. (“Weight Watchers” or “the Company”) (NASDAQWW). Investors who purchased Weight Watchers securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/WW.

NetworkNewsWire Editorial Coverage : On Sept. 20, 2019, history was made when the U.S. Food and Drug Administration approved Rybelsus as the first oral glucagon-like peptide-1 (GLP-1) agonist for type 2 diabetes (T2D). However, it wasn’t just a milestone for T2D management. It was a turning point in medicine, opening the floodgates to a universe of potential therapeutic applications for this remarkable molecule. While undeniably transformative for diabetes and weight loss, GLP-1’s reach now extends far beyond, likely surpassing even the wildest dreams of its creators. From Alzheimer’s and Parkinson’s to drug addiction, clinical trials are painting a stunning picture of GLP-1’s versatility. And it doesn’t stop there. Strong evidence points to opportunities in heart disease, chronic kidney disease and a plethora of other conditions. The newfound applications of this super-drug re-enforce the significant potential for Lexaria Bioscience Corp. (NASDAQLEXX) ( Profile ), with its powerful DehydraTECH(TM) drug-delivery formulation and processing technology that improves both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. Lexaria joins other companies, including Amgen Inc. NASDAQ: AMGNNASDAQAMGN)(NYSE: LLYNYSELLY , Roche (OTCQX: RHHBY) and WW International Inc. (NASDAQ: WWNASDAQ) , that are committed to providing powerhouse solutions in the fields of diabetes, weight loss and more.

EQNX::TICKER_START (NASDAQLEXX),NASDAQ:AMGNNASDAQAMGN)(NYSE:LLYNYSELLY,(OTCQX:RHHBY),(NASDAQ:WWNASDAQ) EQNX::TICKER_END

Stocks finished the week looking for direction after a hotter-than-expected Jobs report and as investors wait for inflation information and big bank earnings

Oprah Winfrey revealed she has lost over 60 pounds and is on the path to reaching her weight goal of 167 lbs. She credits this to taking GLP-1 medication

The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs, led by the popularity of Ozempic. Celebrity usage

Growth or value? Top or bottom line? While investing in stocks with both is preferable, they tend to be expensive. Stocks that meet

The world’s largest virtual healthcare services provider Teladoc Health Inc. (NYSETDOC) stock is finally breaking out of its year-long bearish weekly descend

Shares of WW International, Inc. (NASDAQWW) traded at a new 52-week high today and are currently trading at $11.61. So far today, approximately 6.06M shares have been exchanged, as compared to an average 30-day volume of 2.37M shares.

Accolade Inc. (NASDAQACCD) provides an artificial intelligence (AI)-powered healthcare platform. Learn more about Accolade Inc. stock.

WW International, Inc. (NASDAQWW) has caught the attention of the investment community today with its bullish price action. The company’s shares are currently up 10.42% on the day to $8.48.

Weight management meals and services provider WW International Inc. (NYSEWW) stock made a 52-week high of $10.02 after its Q1 2023 earnings release. Shares

Virtual healthcare services company Teladoc Health Inc. (NYSETDOC) has had a treacherous journey rising to a high of $308 in Feb 2021 and falling to a post-

The topic of weight loss drugs has been making recent headlines. The positive phase 1 clinical trial for Viking Therapeutics Inc. (NASDAQVKTX) GLP-1 treatme

The market continues to seek direction, but the MarketBeat analysts are helping you find opportunities. Here are some of this week's most popular articles.

Weight management meals and services provider WW International Inc. (NYSEWW) spike over 25% as it closed its acquisition of telehealth weight loss platform

WW International, Inc. (NASDAQWW) is one today’s most active stocks by volume. So far today, approximately 37.26M shares of WW International, Inc. have been exchanged, as compared to an average 30-day volume of 3.05M shares.

WW International, Inc. (NASDAQWW), or WeightWatchers, describes itself as a human-focused technology company that offers a “proven, science-based, clinically

NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQWW) (“WeightWatchers,” “WW,” or “the Company”) will release its results for the third quarter 2022 after market close on Thursday, November 3, 2022.

NetworkNewsWire Editorial Coverage: Navigating today’s healthcare systems can be overwhelming. Outrageous costs combined with complex processes have created a healthcare system renowned for overpriced inefficiency; PolicyAdvice reported that in 2018, the global healthcare market topped $8.45 trillion, which represents about 10% of GDP in developed countries. Clearly the industry is desperate for solutions that both improve health outcomes and lower costs. As with many sectors, those solutions are found in technology. Savvy companies operating in the space are recognizing the power healthcare technology (healthtech) and medical technology (medtech) wield in offering next-generation innovation that answers the call to both flatten the healthcare spending curve and provide patients and providers with treatments that work. Already in place prior to COVID-19, the healthcare tech trend has only accelerated adoption of self-diagnostic and remote solutions that have been welcomed by all. Some companies, such as Nemaura Medical Inc. (NASDAQNMRD) (Profile), are focusing on specific areas of unmet medical need, including diabetes and obesity. Nemaura is joined by other astute companies, such as WW International Inc. NASDAQ: WWNASDAQWW)(NYSE: TDOCNYSETDOC, DexCom Inc. (NASDAQ: DXCMNASDAQ) and DarioHealth Corp. (NASDAQ: DRIODRIO), who are also recognized leaders in these sectors as they work to provide…